The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy

Chun Te Wu, Wen Cheng Chen, Shuen Kuei Liao, Cheng Lung Hsu, Kuan Der Lee, Miao Fen Chen

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Hormone therapy for prostate cancer eventually fails leading to a stage called hormone-resistant (HR) disease. To investigate the issue about the characteristics and the radiation response in HR prostate cancer, we established HR cell sub-lines, 22RV1-F and 22RV1-DF, from 22RV1 cells with androgen deprivation for 16 weeks, and obtained LNCaP-HR from LNCaP with long-term bicalutamide treatment. We examined their sensitivities to radiation therapy and the underlying mechanisms. In vitro and in vivo faster tumor growth rate was noted in the HR prostate cancer cells when compared with control. Moreover, HR prostate cancer cells had greater capacity to scavenge reactive oxygen species, and suffered less apoptosis and senescence, and subsequently were more likely to survive from irradiation as measured by clonogenic assay in vitroana growth delay in vivo. The decreased p53 and increased mouse double minute 2 oncogene (MDM2) might be the potential underlying mechanisms for the more aggressive growth and more radioresistance in H R prostate cancer cells. In conclusion, HR prostate cancer cells appeared to be more aggressive in tumor growth and in resistance to radiation treatment. Regulation of the expressions of p53 and MDM2 should be the promising treatment strategies for relative radioresistant prostate cancer.

Original languageEnglish
Pages (from-to)633-643
Number of pages11
JournalEndocrine-Related Cancer
Volume14
Issue number3
DOIs
Publication statusPublished - Sep 2007
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Hormones
Radiation
Therapeutics
Growth
Oncogenes
Androgens
Reactive Oxygen Species
Neoplasms
Radiotherapy
Apoptosis
Cell Line

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Cite this

The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. / Wu, Chun Te; Chen, Wen Cheng; Liao, Shuen Kuei; Hsu, Cheng Lung; Lee, Kuan Der; Chen, Miao Fen.

In: Endocrine-Related Cancer, Vol. 14, No. 3, 09.2007, p. 633-643.

Research output: Contribution to journalArticle

Wu, Chun Te ; Chen, Wen Cheng ; Liao, Shuen Kuei ; Hsu, Cheng Lung ; Lee, Kuan Der ; Chen, Miao Fen. / The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. In: Endocrine-Related Cancer. 2007 ; Vol. 14, No. 3. pp. 633-643.
@article{f9a7b119fe7a4079be449f471f0d17e2,
title = "The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy",
abstract = "Hormone therapy for prostate cancer eventually fails leading to a stage called hormone-resistant (HR) disease. To investigate the issue about the characteristics and the radiation response in HR prostate cancer, we established HR cell sub-lines, 22RV1-F and 22RV1-DF, from 22RV1 cells with androgen deprivation for 16 weeks, and obtained LNCaP-HR from LNCaP with long-term bicalutamide treatment. We examined their sensitivities to radiation therapy and the underlying mechanisms. In vitro and in vivo faster tumor growth rate was noted in the HR prostate cancer cells when compared with control. Moreover, HR prostate cancer cells had greater capacity to scavenge reactive oxygen species, and suffered less apoptosis and senescence, and subsequently were more likely to survive from irradiation as measured by clonogenic assay in vitroana growth delay in vivo. The decreased p53 and increased mouse double minute 2 oncogene (MDM2) might be the potential underlying mechanisms for the more aggressive growth and more radioresistance in H R prostate cancer cells. In conclusion, HR prostate cancer cells appeared to be more aggressive in tumor growth and in resistance to radiation treatment. Regulation of the expressions of p53 and MDM2 should be the promising treatment strategies for relative radioresistant prostate cancer.",
author = "Wu, {Chun Te} and Chen, {Wen Cheng} and Liao, {Shuen Kuei} and Hsu, {Cheng Lung} and Lee, {Kuan Der} and Chen, {Miao Fen}",
year = "2007",
month = "9",
doi = "10.1677/ERC-07-0073",
language = "English",
volume = "14",
pages = "633--643",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "3",

}

TY - JOUR

T1 - The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy

AU - Wu, Chun Te

AU - Chen, Wen Cheng

AU - Liao, Shuen Kuei

AU - Hsu, Cheng Lung

AU - Lee, Kuan Der

AU - Chen, Miao Fen

PY - 2007/9

Y1 - 2007/9

N2 - Hormone therapy for prostate cancer eventually fails leading to a stage called hormone-resistant (HR) disease. To investigate the issue about the characteristics and the radiation response in HR prostate cancer, we established HR cell sub-lines, 22RV1-F and 22RV1-DF, from 22RV1 cells with androgen deprivation for 16 weeks, and obtained LNCaP-HR from LNCaP with long-term bicalutamide treatment. We examined their sensitivities to radiation therapy and the underlying mechanisms. In vitro and in vivo faster tumor growth rate was noted in the HR prostate cancer cells when compared with control. Moreover, HR prostate cancer cells had greater capacity to scavenge reactive oxygen species, and suffered less apoptosis and senescence, and subsequently were more likely to survive from irradiation as measured by clonogenic assay in vitroana growth delay in vivo. The decreased p53 and increased mouse double minute 2 oncogene (MDM2) might be the potential underlying mechanisms for the more aggressive growth and more radioresistance in H R prostate cancer cells. In conclusion, HR prostate cancer cells appeared to be more aggressive in tumor growth and in resistance to radiation treatment. Regulation of the expressions of p53 and MDM2 should be the promising treatment strategies for relative radioresistant prostate cancer.

AB - Hormone therapy for prostate cancer eventually fails leading to a stage called hormone-resistant (HR) disease. To investigate the issue about the characteristics and the radiation response in HR prostate cancer, we established HR cell sub-lines, 22RV1-F and 22RV1-DF, from 22RV1 cells with androgen deprivation for 16 weeks, and obtained LNCaP-HR from LNCaP with long-term bicalutamide treatment. We examined their sensitivities to radiation therapy and the underlying mechanisms. In vitro and in vivo faster tumor growth rate was noted in the HR prostate cancer cells when compared with control. Moreover, HR prostate cancer cells had greater capacity to scavenge reactive oxygen species, and suffered less apoptosis and senescence, and subsequently were more likely to survive from irradiation as measured by clonogenic assay in vitroana growth delay in vivo. The decreased p53 and increased mouse double minute 2 oncogene (MDM2) might be the potential underlying mechanisms for the more aggressive growth and more radioresistance in H R prostate cancer cells. In conclusion, HR prostate cancer cells appeared to be more aggressive in tumor growth and in resistance to radiation treatment. Regulation of the expressions of p53 and MDM2 should be the promising treatment strategies for relative radioresistant prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=35948985191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948985191&partnerID=8YFLogxK

U2 - 10.1677/ERC-07-0073

DO - 10.1677/ERC-07-0073

M3 - Article

C2 - 17914094

AN - SCOPUS:35948985191

VL - 14

SP - 633

EP - 643

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 3

ER -